ARA-290: The Tissue-Repair Peptide Gaining Attention in 2026
ARA-290, also known as Cibinetide or Helix B Surface Peptide (HBSP), is an experimental peptide attracting growing interest in peptide research because of its potential role in tissue protection, inflammation regulation and nerve repair.
Unlike many research peptides, ARA-290 was specifically engineered from a portion of erythropoietin (EPO) while attempting to retain EPO's tissue-protective properties without stimulating red blood cell production.
What Is ARA-290?
ARA-290 is a small 11-amino-acid peptide derived from the structure of erythropoietin.
EPO is best known for stimulating red blood cell production, but researchers discovered that it also activates pathways involved in protecting damaged or stressed tissues.
ARA-290 was developed to investigate whether these protective effects could be separated from EPO's blood-forming activity. Research indicates that ARA-290 does not produce the same erythropoietic effect associated with conventional EPO.
Why Are Researchers Interested in ARA-290?
🧠 Nerve & Neuropathy Research
One of the most studied areas for ARA-290 is peripheral nerve damage and small-fibre neuropathy.
Human clinical research has examined ARA-290 in individuals experiencing neuropathic symptoms associated with conditions including type 2 diabetes and sarcoidosis.
A Phase 2 study involving people with type 2 diabetes and painful neuropathy reported improvements in neuropathic symptom scores and changes in corneal nerve fibre density following ARA-290 administration.
🔥 Inflammation & Tissue Protection
ARA-290 is being investigated for its ability to interact with tissue-protective signalling pathways activated following cellular stress or injury.
Experimental research suggests these pathways may influence:
- inflammatory signalling
- cellular survival
- tissue repair
- oxidative stress
- apoptosis
- nerve regeneration
ARA-290 has demonstrated tissue-protective activity across numerous preclinical models involving the nervous system, kidneys, cardiovascular system and other tissues.
ARA-290 & Small-Fibre Neuropathy
Small-fibre neuropathy affects the small sensory nerves responsible for sensations such as pain, temperature and touch.
ARA-290 has attracted particular attention in this field.
A randomized double-blind pilot study investigated ARA-290 in patients with sarcoidosis experiencing symptoms of small-fibre neuropathy, contributing to further clinical research into the peptide's potential tissue-repair mechanisms.
ARA-290 vs Erythropoietin
The distinction between the two compounds is particularly interesting.
Erythropoietin (EPO) activates pathways responsible for red blood cell production as well as tissue protection.
ARA-290, by contrast, was engineered to investigate the tissue-protective component without significantly stimulating erythropoiesis.
This makes ARA-290 an important research molecule for scientists investigating EPO-related repair pathways without the increase in haematocrit associated with conventional EPO.
A Promising Area of Peptide Research
ARA-290 remains an experimental research peptide, but its unusual mechanism and existing human clinical research make it particularly interesting within the rapidly developing peptide field.
Research continues into its potential relationship with:
nerve regeneration • neuropathic signalling • tissue protection • inflammatory pathways • cellular repair
As peptide research develops, ARA-290 is likely to remain an important compound for researchers investigating how the body's natural repair systems respond to injury and inflammation.
Explore ARA-290 Research Peptides
Biolabs Research ARA-290 is available for laboratory and research purposes.
For research and educational purposes only.